Journal of Cardiovascular Disease Research
ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

A Review on Lemborexant Drug Used For Insomnia

Dr.Swapna Goday, Dasari Shiny Grace
Department of Pharmaceutical Analysis, Niramala college of Pharmacy, Atmakur, Mangalagiri,Guntur, Andhra pradesh - 522502, India
Corresponding Author: Shiny Grace DasariDepartment of Pharmaceutical Analysis, Nirmala college of pharmacy, Acharya Nagarjuna University,Guntur - 522426 , Andhra Pradesh , India

ABSTRACT:
Decreased sleep and wakefulness control cycles can lead to insomnia, which is characterized by difficulty in starting and/or maintaining sleep and is associated with daytime disability. Lemborexant, an antagonist of the orexin receptor, is used for insomnia approved by the US FDA. Lemborexant is safe for use in patients with obstructive sleep apnea (OSA). The neuropeptides binding block that stimulates orexin A and orexin B to the orexin receptors OX1R and OX2R are thought to suppress the wake drive. CYP3A inducers of Itraconazole, clarithromycin, Fluconazole, and verapamil in combination or with lemborexant may increase the adverse effects. Study1, Long-term effectiveness and safety of lemborexant in adults with insomnia disorder. Study 2, multicenter, randomized, blind-blind, placebo-controlled, active comparator, parallel-group Phase III learning lemborexant performance and safety in 1,006 patients aged 55 years and older 45% of all patients were 65 years of age and older insomnia began in North America and Europe. Study 3, Studying 108 was a randomized, double-blind, four-term crossover study that examined the effects of lamborexantine on posture condition, hearing impairment, and brain function in 56 healthy volunteers aged 55 and over. study 4, was 1 month, randomized, blind-blind, placebo- and actively controlled, multicenter, placebo-controlled trial in adult patients aged 55 and over and male patients 65 years and older who met the DSM-5 procedure. Study 5, Sunrise 2 is a 12-page multi-page, global, randomized, placebo-controlled, blind, phase III study of 949 adult male and female participants in Japan, North America, South America, Europe, Asia, Asia, and Oceania.
KEYWORDS: Lemborexant, sleep, orexin, study, insomni

1. INTRODUCTION:

Decreased sleep and wakefulness control cycles can lead to insomnia, which is characterized by difficulty in starting and/or maintaining sleep and is associated with daytime disability. Current treatments for insomnia include behavioral insomnia treatments, benzodiazepines, non -benzodiazepine hypnotics, orexin receptor antagonists, melatonin receptor agonists, and antidepressants [1, 2]. Lemborexant, an antagonist of the orexin receptor, is used for insomnia approved by the US FDA. The chemical name is (1R, 2S) -2-{[(2, 4-dimethyl pyrimidin-5-yl) oxy] methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl) cyclopropane carboxamide. The formula is C22H20F2N4O2. The molecular weight is 410.42 [3]. Women are 1.4 times more than men to suffer from insomnia. Older people also have higher incidences of insomnia due to changes in sleep patterns, including sleep disturbances, frequent waking, and waking up in the morning, which may change to less sleep [4]

1.1 Indication

Lemborexant is safe for use in patients with obstructive sleep apnea (OSA). No other indications are currently approved for the use of lemborexant, although it is currently being used to treat the arousal rhythm in patients with Alzheimer's disease and is currently being investigated. [5]

1.2 Mechanism of action

The mechanism of action of lemborexant in the treatment of insomnia is characterized by difficulty with sleep onset and/or sleep retention, which is thought to antagonize orexin receptors by signaling systems of orexin neuropeptides, contributing to excitability. The neuropeptides binding block that stimulates orexin A and orexin B to the orexin receptors OX1R and OX2R are thought to suppress the wake drive. Lemborexant binds to the orexin receptors OX1R and OX2R and acts as a strong competitor to block OX2R [6]. While orexin-A acts indiscriminately on both orexin-1 receptor (OX1R) and orexin-2 receptors (OX2R), orexin B acts selectively on OX2R. Produced in the hypothalamus, orexin peptides are released from between 50,000 and 80,000 neurons that produce orexin in the human brain [6, 7].

1.3 Dosage

The dose of lemborexant is 5 mg should be taken not more than once a night before bedtime with at least 7 hours before the scheduled waking time. The dose may be increased to the recommended dose of 10 mg depending on the clinical response and tolerance. The clinical dose of lemborexant should not exceed 10 mg [8, 9].

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

1.4 **Adverse effects**

1.4.1 Usual

Sleepiness/ drowsiness, tiredness, lethargy, generalized weakness, fatigue, sleep paralysis, hallucinations, depression [10].

1.4.2 Rare

Irritability, anorexia, behavioral changes, mood disturbances, suicidal tendency, disorientation [7, 10].

1.5 Contraindications

This drug is contraindicated in Narcolepsy [11]

1.6 Modification in dosage

1.6.1 In Hepatic impairment

Increased somnolence in mild with no dose alteration, should not suggest more than 5mg in moderate and no evidence of occurrence in severe hepatic impairment [12].

1.7 Drug Interactions

CYP3A inducers of Itraconazole, clarithromycin, Fluconazole, and verapamil in combination or with lemborexant may increase the adverse effects. Using rifampin, carbamazepine, bosentan, efavirenz, etravirine, and modafinil of CYP3A inducers along with lemborexant may decrease the effectiveness of the drug.[12] tobacco and alcohol drinking may cause interactions', ethanol and grape juice shouldn't be taken while using lemborexant. [13]

1.8 Precautions

1.8.1 In pediatrics and geriatrics

Appropriate studies have not been conducted on the relationship between age and lemborexant effects in children. Safety and efficiency are not yet established. Appropriate research to date has not shown any health-related problems that could reduce the use of lemborexant in the elderly. However, drowsiness, drowsiness, and falls are more likely in older people, who are more sensitive than older people to the effects of lemborexant.

1.8.2 In Breastfeeding

There were no enough studies to evaluate the potential benefits and address the potential risks before taking this medication while breastfeeding. [14]

1.8.3 In Effects of CNS depressant

Driving ability did not work well in some studies taking lemborexant 10 mg. The risk of daytime disability increasesif the lemborexant is taken less than the rest of the night or if the recommended dose is taken. If lemborexant is takenin these cases, patients should be warned about driving and other things that require full mental alertness. Using hypnotics along with lemborexant may cause more suicidal tendencies or severe depression. [1, 11]

2. Pharmacokinetics

2.1 Absorption:

Lemborexant takes 1-3 hours to reach peak concentration.

2.2 Effect of food on the stomach:

With high-fat and high-calorie meals with around 500 to 600 calories, maximum plasma concentration (C max) will decrease by 23%, 18% increase in AUC0-inf, and 2hours delay in tmax.

2.3 Distribution of lemborexant:

The drug shows a 1970l pf volume of distribution.

In in-vitro studies, it shows 94% of protein binding capacity.

2.4 Metabolism

The drug Lemborexant is mainly metabolized by the CYP3A4 enzymes and CYP3A5 with an M10as major metabolite. [15]

2.5 Excretion:

Majorly through feces with 57.4% and through urine with 2.1% in unchanged form.

The half-life for the elimination of lemborexant dosage was 17 and 19 hours in 5 mg and 10 mg doses, respectively. Age, body mass index (BMI), race, or gender do not contribute to the elimination of a half-life of a drug. [16, 17]

3. Various clinical study reports

3.1 In study 1, Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial by Jane Yardley et.al., described in the study with 303 of about 12 months. It was a randomized controlled placebo for the first six months and then a double-blind, parallel-group phase3 study. This study states that for insomnia having sleep onset and/or sleep difficulty treatment lemborexant has worked effectively. This drug can have benefits in long-term use for adults with reduction of insomnia. [18]

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

3.2 In study 2, multicenter, randomized, blind-blind, placebo-controlled, active comparator, parallel-group Phase III learning lemborexant performance and safety in 1,006 patients aged 55 years and older 45% of all patients were 65 years of age and older insomnia began in North America and Europe. SUNRISE 1 includes a pre-randomized phase of up to 35 days including a placebo start-up period of two weeks and a random exercise phase with a 30-day treatment period and two weeks of pre-study and patients were given a placebo or one type of three-drug regimen lemborexant5 mg, lemborexant 10 mg, Zolpidem ER 6.25 mg.[19]

3.3 In study 3, Studying 108 was a randomized, double-blind, four-term crossover study that examined the effects of lamborexantine on posture condition, hearing impairment, and brain function in 56 healthy volunteers aged 55 and over. Participants were treated with a single dose of placebo, lemborexant 5 mg, lemborexant 10 mg, or zolpidem ER 6.25 mg at bedtime. The last point that examined the intensity of the background was when aroused by the alarm about four hours after the handling of the lemborexant, compared to zolpidem ER as measured with a stabilometer. While there has been a significant statistical increase in the human body of both lemborexant doses compared with placebo, zolpidem ER increased physical activity by almost three times more than lemborexant. This increase was threefold with zolpidem which was associated with the content of alcohol in the blood (BAC of 0.05 percent) near the official driving limit. The next morning, just after the end of eight hours in bed, the lemborexant dose did not have a statistically significant effect on this postoperative intensity level compared to placebo, in contrast to zolpidem ER. [20]

3.4 In study 4, It was 1 month, randomized, blind-blind, placebo- and actively controlled, multicenter, placebo-controlled trial in adult patients aged 55 and overand male patients 65 years and older who met the DSM-5 procedure. With insomnia. Patients were randomly assigned to placebo (n = 208), lemborexant 5 mg (n = 266) or 10 mg (n = 269), or an active dose (n = 263) once a night. The personality and basic characteristics of the patients in Study 2 were similar to treatment arms. Patients were a median age of 63 years (range 55 to 88) and were 86% female, 72% White, 25% Black or African American, and another 2%; 45% of the elderly (≥65 years). The lemborexant 5 mg and 10 mg showed a statistically significant increase in baseline performance, LPS, compared with placebo (Table 4). The lemborexant 5 mg and 10 mg showed significant statistical improvements in SEF and WASO compared with placebo. [21]

3.5 In study 5, Sunrise 2 is a 12-page multi-page, global, randomized, placebo-controlled, blind, phase III study of 949 adult male and female participants in Japan, North America, South America, Europe, Asia, Asia, and Oceania. A placebo-controlled duration of six months, treatment of active treatment only, and two weeks without treatment before the end of the study. A Lemborexant 5 mg, 10 mg, or similar placebo was taken as a tablet at home every night before the patient tried to sleep for the first six months of the study. Patients receiving a placebo during the first six months were given lemborexant 5 mg or 10 mg over six months. Patients receiving effective treatment at the beginning of the course continued treatment at random. The primary outcome measure was a change from the baseline before the first sleep delay after six months of placebo-controlled treatment. The primary measures of secondary outcomes meant a change from baseline to sleep function and wakefulness independently after the onset of sleep after six months of placebo-controlled treatment. From the results, the main endpoint and every second point of efficacy was achieved in the arms of the lemborexant, and significant statistical improvement at the beginning of sleep and sleep retention was confirmed with the lemborexant. arms compared with placebo during the first six months of treatment. The most common AEs in lambrexant arms were somnolence, nasopharyngitis, headache, and fever. [22]\

REFERENCES:

1. Sateia MJ, Buysse DJ, Krystal AD. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: anAmerican Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2017; 13: 307e49.
2. Riemann D, Nissen C, Palagini L. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015; 14(5):547–558.
3. Pagel JF. Drug-induced hypersomnolence. Sleep Med Clin. 2017;12 (3):383–393.
4. Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017;89(12):1244-1250.
5. Cheng JY, Filippov G, Moline M, Zammit GK, Bsharat M, Hall N, Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

controlled, crossover study. Journal of sleep research. 2020 Mar 18.

6. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS, Neurons containing hypocretin (orexin) project to multiple neuronal systems. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1998 Dec 1.

7. Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A, Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine. 2017 Nov 15.

8. Asnis GM, Thomas M, Henderson MA, Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. International journal of molecular sciences. 2015 Dec 30.

9. Bertisch SM, Herzig SJ, Winkelman JW, et al. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 2014; 37:343e9.

10. Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther. 2015;9:6035–6042.

11. Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M, Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended-Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA network open. 2019 Dec 2.

12. Landry I, Nakai K, Ferry J. Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending dose Phase 1 studies in healthy adults [published online ahead of print, 2020 May 28]. Clin Pharmacol Drug Dev. 2020; 10.1002.

13. Eisai Inc. DAYVIGO (lemborexant) [Prescribing Information]. 2019. Woodcliff Lake, NJ: Eisai Inc.

14. Vermeeren A, Sun H, Vuurman EF, et al. On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40 mg: a study in non-elderly healthy volunteers. Sleep. 2015;38 (11):1803–1813.

15. Riemann D, Baglioni C, Bassetti C. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017; 26:675e700.

16. schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008; 4: 487e504.

17. Lee JY, Farrell B, Holbrook AM. Deprescribing benzodiazepine receptor agonists are taken for insomnia: a review and key messages from practice guidelines. Pol Arch Intern Med 2019; 129:43e9.

18. Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med. 2021 Apr; 80:333-342.

19. Eisai Inc. A multicenter, randomized, double-blind, placebo-controlled, active comparator, parallel-group study of the efficacy and safety of lemborexant in subjects 55 years and older with insomnia disorder. (E2006-G000-304). (Clinicaltrials.gov Identifier NCT02783729). 2018. Unpublished data on file.

20. Eisai Inc. A randomized, double-blind, placebo-controlled, and active-comparator, 4-period crossover study evaluates the effect of DAYVIGO versus placebo and zolpidem on postural stability, auditory awakening. (E2006-A001-108). (Clinicaltrials.gov Identifier NCT03008447). 2017. Unpublished data on file.

21. Beuckmann CT, Suzuki M, Ueno T, et al. In vitro and silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017; 362(2):287–295.

22. Eisai Inc. A randomized, double-blind, placebo- and active-controlled, 4-period crossover study evaluates the effect of DAYVIGO versus placebo on driving performance in healthy adult and elderly subjects. (E2006-E044-106). (Clinicaltrials.gov Identifier NCT02583451). 2017. Unpublished data on file.